CLOs on the Move

Cognito Therapeutics

www.cognitotx.com

 
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer`s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer`s disease and expects to start pivotal studies in 2022. The company`s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cognitotx.com
  • 1218 Massachusetts Avenue
    Cambridge, MA USA 02138
  • Phone: 857.201.5088

Executives

Name Title Contact Details
Jennifer Newberger
 Vice President, Head of Regulatory Affairs and Compliance Profile

Similar Companies

University Compounding Pharmacy

University Compounding Pharmacy is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hero Practice Services

Phenomenome Discoveries

Phenomenome Discoveries, Inc. is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Bracco Diagnostics

Established in August 1994, Bracco Diagnostics Inc. develops and markets a wide range of diagnostic imaging agents in the U.S. Bracco products are currently used in conjunction with X-ray, CT, MRI, and nuclear medicine. Bracco Diagnostics Inc. is a

Onyx Pharmaceuticals

At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve.   By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.